• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在高效抗逆转录病毒治疗时代,与普通人群相比,诊断出 HIV 的人群的死亡率和死因:一项全国性观察队列分析。

Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.

机构信息

Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK; Centre for Sexual Health and HIV Research, Department of Infection and Population Health, University College London, London, UK.

Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK.

出版信息

Lancet Public Health. 2017 Jan;2(1):e35-e46. doi: 10.1016/S2468-2667(16)30020-2. Epub 2016 Dec 15.

DOI:10.1016/S2468-2667(16)30020-2
PMID:29249478
Abstract

BACKGROUND

Deaths in HIV-positive people have decreased since the introduction of highly active antiretroviral therapy (HAART) in 1996. Fewer AIDS-related deaths and an ageing cohort have resulted in an increase in the proportion of HIV patients dying from non-AIDS-related disorders. Here we describe mortality and causes of death in people diagnosed with HIV in the HAART era compared with the general population.

METHODS

In this observational analysis, we linked cohort data collected by Public Health England (PHE) for individuals aged 15 years and older, diagnosed with HIV in England and Wales from 1997 to 2012, to the Office for National Statistics (ONS) national mortality register. Cohort inclusion began at diagnosis with follow-up clinical information collected every year from all 220 National Health Service (NHS) HIV outpatient clinics nationwide. To classify causes of death we used a modified Coding Causes of Death in HIV (CoDe) protocol, which uses death certificate data and clinical markers. We applied Kaplan-Meier analysis for survival curves and mortality rate estimation and Cox regression to establish independent predictors of all-cause mortality, adjusting for sex, infection route, age at diagnosis, region of birth, year of diagnosis, late diagnosis, and history of HAART. We used standardised mortality ratios (SMRs) to make comparisons with the general population.

FINDINGS

Between 1997 and 2012, 88 994 people were diagnosed with HIV, contributing 448 839 person-years of follow up. By the end of 2012, 5302 (6%) patients had died (all-cause mortality 118 per 10 000 person-years, 95% CI 115-121). In multivariable analysis, late diagnosis was a strong predictor of death (hazard ratio [HR] 3·50, 95% CI 3·13-3·92). People diagnosed more recently had a lower risk of death (2003-07: HR 0·66, 95% CI 0·62-0·70; 2008-12: HR 0·65, 95% CI 0·60-0·71). Cause of death was determinable for 4808 (91%) of 5302 patients; most deaths (2791 [58%] of 4808) were attributable to AIDS-defining illnesses. Cohort mortality was significantly higher than the general population for all causes (SMR 5·7, 95% CI 5·5-5·8), particularly non-AIDS infections (10·8, 9·8-12·0) and liver disease (3·7, 3·3-4·2). All-cause mortality was highest in the year after diagnosis (SMR 24·3, 95% CI 23·4-25·2).

INTERPRETATION

Despite the availability of free treatment and care in the UK, AIDS continues to account for the majority of deaths in HIV-positive people, and mortality remains higher in HIV-positive people than in the general population. These findings highlight the importance of prompt diagnosis, care engagement, and optimum management of comorbidities in reducing mortality in people with HIV.

FUNDING

Public Health England.

摘要

背景

自 1996 年引入高效抗逆转录病毒疗法(HAART)以来,艾滋病毒阳性人群的死亡人数有所下降。艾滋病相关死亡人数减少和年龄较大的人群导致因非艾滋病相关疾病而死亡的艾滋病毒患者比例增加。在这里,我们描述了在 HAART 时代与普通人群相比,艾滋病毒感染者的死亡率和死亡原因。

方法

在这项观察性分析中,我们将英格兰和威尔士 1997 年至 2012 年间诊断出的艾滋病毒感染者的公共卫生英格兰(PHE)收集的队列数据与国家统计局(ONS)国家死亡率登记处进行了关联。队列纳入始于诊断时,每年从全国 220 家国家卫生服务(NHS)艾滋病毒门诊诊所收集临床信息。为了分类死因,我们使用了改良的 HIV 死因编码(CoDe)方案,该方案使用死亡证明数据和临床标志物。我们应用 Kaplan-Meier 分析生存曲线和死亡率估计,并应用 Cox 回归确定全因死亡率的独立预测因素,调整性别、感染途径、诊断时年龄、出生地、诊断年份、晚期诊断和 HAART 治疗史。我们使用标准化死亡率比(SMR)与普通人群进行比较。

结果

在 1997 年至 2012 年间,有 88994 人被诊断出患有 HIV,随访时间为 448839 人年。截至 2012 年底,5302 人(6%)死亡(全因死亡率为每 10000 人年 118 人,95%CI 115-121)。在多变量分析中,晚期诊断是死亡的一个强有力的预测因素(危险比[HR]3.50,95%CI 3.13-3.92)。最近诊断的患者死亡风险较低(2003-07:HR 0.66,95%CI 0.62-0.70;2008-12:HR 0.65,95%CI 0.60-0.71)。4808 名(91%)5302 名患者的死因可确定;大多数死亡(4808 名中的 2791 名[58%])归因于艾滋病定义性疾病。所有原因的队列死亡率均显著高于普通人群(SMR 5.7,95%CI 5.5-5.8),尤其是非艾滋病感染(10.8,9.8-12.0)和肝脏疾病(3.7,3.3-4.2)。诊断后第一年的全因死亡率最高(SMR 24.3,95%CI 23.4-25.2)。

解释

尽管英国提供了免费的治疗和护理,但艾滋病仍然是艾滋病毒阳性人群死亡的主要原因,艾滋病毒阳性人群的死亡率仍然高于普通人群。这些发现强调了及时诊断、护理参与以及最佳管理合并症对于降低艾滋病毒感染者的死亡率的重要性。

资金

英国公共卫生署。

相似文献

1
Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.在高效抗逆转录病毒治疗时代,与普通人群相比,诊断出 HIV 的人群的死亡率和死因:一项全国性观察队列分析。
Lancet Public Health. 2017 Jan;2(1):e35-e46. doi: 10.1016/S2468-2667(16)30020-2. Epub 2016 Dec 15.
2
Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer.在抗逆转录病毒治疗时代,英格兰和威尔士诊断出 HIV 感染者的十年死亡率趋势:艾滋病仍然是无声的杀手。
HIV Med. 2013 Nov;14(10):596-604. doi: 10.1111/hiv.12045. Epub 2013 May 15.
3
Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland.英格兰、威尔士和北爱尔兰的结核病对艾滋病毒感染者生存状况的影响。
Thorax. 2015 Jun;70(6):566-73. doi: 10.1136/thoraxjnl-2014-206452. Epub 2015 Mar 24.
4
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.高效抗逆转录病毒治疗时代的死亡率:HIV门诊研究中死亡和疾病原因的变化
J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34. doi: 10.1097/01.qai.0000233310.90484.16.
5
Excess mortality related to circulatory system diseases and diabetes mellitus among Italian AIDS patients vs. non-AIDS population: a population-based cohort study using the multiple causes-of-death approach.意大利艾滋病患者与非艾滋病人群心血管疾病和糖尿病相关超额死亡率的比较:基于人群的使用多死因方法的队列研究。
BMC Infect Dis. 2018 Aug 28;18(1):428. doi: 10.1186/s12879-018-3336-x.
6
Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.1984年至2003年加拿大艾伯塔省南部HIV感染者的死亡率及死亡原因变化情况
HIV Med. 2005 Mar;6(2):99-106. doi: 10.1111/j.1468-1293.2005.00271.x.
7
Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study.巴西里约热内卢感染艾滋病毒的女性、异性恋男性和男男性接触者的死亡率:一项观察性队列研究。
Lancet HIV. 2016 Oct;3(10):e490-8. doi: 10.1016/S2352-3018(16)30052-2. Epub 2016 Aug 17.
8
Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012.1996年至2012年期间,一个以人群为基础的队列中,感染和未感染艾滋病毒人群的死亡率及死亡原因变化。
BMC Infect Dis. 2017 Feb 27;17(1):174. doi: 10.1186/s12879-017-2254-7.
9
Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.高效抗逆转录病毒治疗时代城市中感染艾滋病毒及有吸毒风险人群队列中的死亡率
Clin Infect Dis. 2005 Sep 15;41(6):864-72. doi: 10.1086/432883. Epub 2005 Aug 16.
10
Concurrent HIV/AIDS diagnosis increases the risk of short-term HIV-related death among persons newly diagnosed with AIDS, 2002-2005.2002年至2005年期间,同时诊断出感染艾滋病毒/艾滋病会增加新诊断出患有艾滋病的人在短期内死于与艾滋病毒相关疾病的风险。
AIDS Patient Care STDS. 2008 Jan;22(1):17-28. doi: 10.1089/apc.2007.0042.

引用本文的文献

1
Sleep and Rest-Activity Rhythms are Delayed and Less Robust in People Living With HIV.感染艾滋病毒的人睡眠及休息-活动节律延迟且稳定性较差。
Open Forum Infect Dis. 2025 Aug 21;12(9):ofaf498. doi: 10.1093/ofid/ofaf498. eCollection 2025 Sep.
2
Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study.埃塞俄比亚西北部德布雷马科斯综合专科医院接受基于多替拉韦的抗逆转录病毒治疗的艾滋病毒感染者的血脂异常及其相关因素:一项横断面研究
AIDS Res Treat. 2025 Aug 5;2025:6621097. doi: 10.1155/arat/6621097. eCollection 2025.
3
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997-2022: Data From the Icona Cohort.
1997 - 2022年意大利HIV感染者的全因死亡率和特定病因死亡率:来自Icona队列的数据。
Open Forum Infect Dis. 2025 Aug 2;12(8):ofaf455. doi: 10.1093/ofid/ofaf455. eCollection 2025 Aug.
4
Increased IFN responses drive myeloid cell activation in people living with HIV-1.在HIV-1感染者中,增强的干扰素反应驱动髓系细胞活化。
Sci Rep. 2025 Jul 1;15(1):20627. doi: 10.1038/s41598-025-04613-0.
5
The prevalence of dyslipidemia and its correlation with anti-retroviral therapy among people living with HIV in China: a systematic review and meta-analysis.中国HIV感染者中血脂异常的患病率及其与抗逆转录病毒治疗的相关性:一项系统评价和荟萃分析。
Front Cardiovasc Med. 2025 Jun 13;12:1498165. doi: 10.3389/fcvm.2025.1498165. eCollection 2025.
6
Causes of death in people living with HIV from a North London cohort between 2006 and 2023: A descriptive analysis.2006年至2023年间伦敦北部一个队列中HIV感染者的死亡原因:描述性分析
HIV Med. 2025 Aug;26(8):1258-1266. doi: 10.1111/hiv.70054. Epub 2025 Jun 4.
7
Prevalence and influencing factors of liver injury in naïve patients with HIV/AIDS in Nanjing from 2005 to 2022: Cross-sectional study.2005年至2022年南京初治HIV/AIDS患者肝损伤的患病率及影响因素:横断面研究
Medicine (Baltimore). 2025 May 30;104(22):e41261. doi: 10.1097/MD.0000000000041261.
8
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy.在HIV-RNA检测不到的艾滋病毒感染者中选定的合并症与抗逆转录病毒治疗转换的概率:意大利的一项回顾性分析
J Antimicrob Chemother. 2025 Jul 1;80(7):1849-1859. doi: 10.1093/jac/dkaf137.
9
Cause of death in people living with HIV who initiated antiretroviral therapy after enrolling to the Thai National AIDS Program from 2008 to 2021.2008年至2021年加入泰国国家艾滋病项目后开始接受抗逆转录病毒治疗的艾滋病毒感染者的死因。
Lancet Reg Health Southeast Asia. 2025 Apr 23;36:100576. doi: 10.1016/j.lansea.2025.100576. eCollection 2025 May.
10
Targeting inflammasomes as a therapeutic potential for HIV/AIDS.将炎性小体作为治疗HIV/AIDS的潜在靶点。
Cell Mol Life Sci. 2025 Apr 17;82(1):162. doi: 10.1007/s00018-025-05685-x.